Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

769
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
769
Data Validation01:03

Data Validation

7.2K
Data validation is an essential part of a comprehensive assessment. Validation is confirming or verifying and opening the door to gathering more assessment data as it clarifies vague or unclear data. The process of checking and verifying the collected information is called data validation. The primary purpose of data validation is to ensure data is as free from error, bias, and misinterpretation as possible.
Nursing assessment guides are generally based on holistic models rather than medical...
7.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

582
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
582
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

347
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
347
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

498
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
498
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

418
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
418

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Risk Factors for Kidney Function in Individuals with Type 1 Diabetes.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Optimization and Parallelization of Sorting by Interfacial Tension (SIFT) for High-Throughput Metabolic Cell Sorting.

Micromachines·2026
Same author

Genome-wide association study of cardiovascular disease in people with HIV from the Million Veteran Program (MVP).

AIDS (London, England)·2026
Same author

Recognising CADASIL in adults with NPH-like syndrome.

BMJ case reports·2026
Same author

Venous sinus stenting worsening in fulminant intracranial hypertension secondary to <i>Cryptococcus gattii</i>: lessons learnt.

BMJ case reports·2026
Same author

Paroxysmal Behavioral Disturbances, Seizures, and Periventricular White Matter Disease Mimicking Leukodystrophy in Niemann-Pick C: A Clinical Vignette.

Pediatric neurology·2026
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K

Inference for Surrogate Endpoint Validation in the Binary Case.

Ionut Bebu1, Thomas Mathew2, Brian Agan3

  • 1a The Biostatistics Center, Department of Epidemiology and Biostatistics , The George Washington University , Rockville , Maryland , USA.

Journal of Biopharmaceutical Statistics
|January 25, 2015
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for validating surrogate endpoints using proportion explained (PE) and relative effect (RE) criteria. The proposed confidence intervals demonstrate superior performance for surrogate endpoint validation in clinical trials.

Keywords:
Causal effectsFiducial intervalGeneralized confidence intervalProportion explainedRelative effect

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K

Related Experiment Videos

Last Updated: Apr 18, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.4K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Epidemiology

Background:

  • Surrogate endpoints are crucial in clinical trials for accelerating drug development.
  • Validating surrogate endpoints requires robust statistical methods to ensure reliability.
  • Existing methods for assessing surrogate endpoint validity may have limitations.

Purpose of the Study:

  • To investigate surrogate endpoint validation for binary surrogate and true endpoints.
  • To evaluate the performance of proportion explained (PE) and relative effect (RE) criteria.
  • To develop and assess novel confidence interval methods for PE and RE.

Main Methods:

  • Utilized generalized confidence intervals and fiducial intervals for computing confidence intervals.
  • Investigated surrogate endpoint validation using proportion explained (PE) and relative effect (RE).
  • Compared proposed methods with traditional approaches like Fieller's theorem and the delta method.

Main Results:

  • The proposed confidence intervals showed satisfactory coverage probability for PE and RE.
  • Intervals based on Fieller's theorem and the delta method exhibited inadequate coverage.
  • The developed methodology is applicable to causal inference-based surrogate endpoint validation.

Conclusions:

  • The novel confidence interval approach provides a reliable tool for surrogate endpoint validation.
  • This method offers improved accuracy compared to existing techniques for binary endpoints.
  • The findings support the application of these statistical techniques in clinical trial design.